HUP9700579A3 - Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation - Google Patents

Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation

Info

Publication number
HUP9700579A3
HUP9700579A3 HU9700579A HUP9700579A HUP9700579A3 HU P9700579 A3 HUP9700579 A3 HU P9700579A3 HU 9700579 A HU9700579 A HU 9700579A HU P9700579 A HUP9700579 A HU P9700579A HU P9700579 A3 HUP9700579 A3 HU P9700579A3
Authority
HU
Hungary
Prior art keywords
flogistic
contg
diseases
preparation
treating tumors
Prior art date
Application number
HU9700579A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9700579(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HU9700579D0 publication Critical patent/HU9700579D0/hu
Publication of HUP9700579A2 publication Critical patent/HUP9700579A2/hu
Publication of HUP9700579A3 publication Critical patent/HUP9700579A3/hu
Publication of HU228764B1 publication Critical patent/HU228764B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU9700579A 1996-03-12 1997-03-12 Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation HU228764B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103866 1996-03-12

Publications (4)

Publication Number Publication Date
HU9700579D0 HU9700579D0 (en) 1997-04-28
HUP9700579A2 HUP9700579A2 (en) 1997-12-29
HUP9700579A3 true HUP9700579A3 (en) 1999-05-28
HU228764B1 HU228764B1 (en) 2013-05-28

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9700579A HU228764B1 (en) 1996-03-12 1997-03-12 Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation

Country Status (24)

Country Link
US (1) US5935995A (hu)
EP (1) EP0795334B1 (hu)
JP (1) JP4392065B2 (hu)
KR (1) KR100466467B1 (hu)
CN (1) CN1168733C (hu)
AT (1) ATE316799T1 (hu)
AU (1) AU708202B2 (hu)
BG (1) BG61900B1 (hu)
BR (1) BRPI9701248B1 (hu)
CA (1) CA2199664C (hu)
CZ (1) CZ297994B6 (hu)
DE (1) DE59712561D1 (hu)
DK (1) DK0795334T3 (hu)
ES (1) ES2257756T3 (hu)
HU (1) HU228764B1 (hu)
NO (1) NO320322B1 (hu)
NZ (1) NZ314368A (hu)
PL (1) PL189604B1 (hu)
RO (1) RO120951B1 (hu)
RU (1) RU2191021C2 (hu)
SG (1) SG50011A1 (hu)
SI (1) SI0795334T1 (hu)
TR (1) TR199700178A2 (hu)
UA (1) UA50719C2 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
DE60233336D1 (de) 2001-08-30 2009-09-24 Chemocentryx Inc Bicyclische verbindungen als hemmer der chemokin-bindung an us28
WO2004000863A1 (ja) * 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. プロドラッグ、その医薬としての使用、およびその製法
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2006038070A2 (en) * 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
WO2008124097A2 (en) * 2007-04-06 2008-10-16 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
EP3380125A4 (en) 2015-11-25 2019-08-28 LegoChem Biosciences, Inc. CONJUGATES WITH PEPTIDE GROUPS AND RELATED METHODS
US11173214B2 (en) 2015-11-25 2021-11-16 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
CN112451682A (zh) 2015-11-25 2021-03-09 乐高化学生物科学股份有限公司 包含自降解基团的缀合物及其相关方法
EP4074328A1 (en) 2015-12-04 2022-10-19 Seagen Inc. Intermediates of conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
CN112135634A (zh) 2018-02-02 2020-12-25 马福瑞克斯肿瘤学股份有限公司 单磷酸吉西他滨的小分子药物偶联物
BR112020022299A2 (pt) 2018-05-09 2021-02-23 Legochem Biosciences, Inc. composições e métodos relacionados a conjugados de anticorpo-fármaco anti-cd19
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
ES2069955T3 (es) * 1991-10-25 1995-05-16 Tungsram Reszvenytarsasag Lampara de descarga de baja presion con un solo casquillo.
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (en) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Also Published As

Publication number Publication date
NO320322B1 (no) 2005-11-21
CA2199664C (en) 2008-05-20
US5935995A (en) 1999-08-10
KR970065550A (ko) 1997-10-13
NZ314368A (en) 1998-10-28
JP4392065B2 (ja) 2009-12-24
EP0795334A3 (de) 1997-09-24
BRPI9701248B1 (pt) 2022-01-18
AU708202B2 (en) 1999-07-29
BR9701248A (pt) 1999-10-13
PL318878A1 (en) 1997-09-15
DE59712561D1 (de) 2006-04-13
TR199700178A2 (tr) 1997-09-21
ES2257756T3 (es) 2006-08-01
NO971116L (no) 1997-09-15
BG101290A (en) 1997-09-30
SI0795334T1 (sl) 2006-06-30
KR100466467B1 (ko) 2005-06-29
MX9701832A (es) 1998-07-31
CA2199664A1 (en) 1997-09-12
ATE316799T1 (de) 2006-02-15
CN1168733C (zh) 2004-09-29
BG61900B1 (bg) 1998-09-30
SG50011A1 (en) 1998-06-15
BR9701248A8 (pt) 2013-06-18
AU1620597A (en) 1997-09-18
RU2191021C2 (ru) 2002-10-20
RO120951B1 (ro) 2006-10-30
HU9700579D0 (en) 1997-04-28
JPH101495A (ja) 1998-01-06
UA50719C2 (uk) 2002-11-15
PL189604B1 (pl) 2005-08-31
CN1163895A (zh) 1997-11-05
EP0795334A2 (de) 1997-09-17
EP0795334B1 (de) 2006-02-01
HUP9700579A2 (en) 1997-12-29
CZ74297A3 (en) 1997-09-17
CZ297994B6 (cs) 2007-05-16
NO971116D0 (no) 1997-03-11
DK0795334T3 (da) 2006-06-06
HU228764B1 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
HUP9700579A3 (en) Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation
ZA971937B (en) Combinations for treatment of proliferative diseases.
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
AU3699397A (en) Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases
ZA967745B (en) Pharmaceutical formulations.
ZA969722B (en) Pharmaceutical formulations.
ZA949344B (en) Treatment of poultry.
BR9608773A (pt) Tratamento bacteriano para silagem
IL118426A (en) Pharmaceutical composition containing 1,3- bis-triazolyl-2-propanol derivative for treating cancer tumors or viruses
AU8800598A (en) B7-binding molecules for treating immune diseases
EP1010435A4 (en) PREPARATIONS OF NANOCAPSULES FOR THE TREATMENT OF INTRA-ARTICULAR DISEASES
PT907358E (pt) Terapia de distribuicao uniforme de droga
AU2508597A (en) Drug for the treatment of tumours
ZA979573B (en) (Alpha-aminophosphino) peptide derivatives, process for their preparation and their therapeutic applications.
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
EP0658115A4 (en) PEPTIDE MEDICINES FOR TREATING DISEASES.
ZA973209B (en) Therapeutic compounds.
IL129927A0 (en) 1,4-Diazabicyclo (2.2.2) oct-2-ylmethyl derivatives their preparation and therapeutic application
HK1010885A1 (en) 10,13,15-trioxatricyclo [9.2.1.1.9.6]-pentadecanone-derivatives, process for their preparation and pharmaceutical containing them
ZA9610278B (en) Pyridylcarbamates, processes and intermediates for their preparation, and their use.
ZA974811B (en) Novel therapeutic compounds.
HUP9600665A3 (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
IL128351A0 (en) Pharmaceutical composition for treating viral diseases
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
ZA964198B (en) Treatment regime for skin.

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees